Aptevo Therapeutics (NASDAQ:APVO) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Aptevo Therapeutics (NASDAQ:APVO) in a research report report published on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Aptevo Therapeutics Trading Down 3.8 %

Shares of NASDAQ:APVO opened at $0.42 on Friday. Aptevo Therapeutics has a 12 month low of $0.28 and a 12 month high of $21.64. The firm’s 50-day moving average is $0.45 and its 200 day moving average is $2.34.

Aptevo Therapeutics (NASDAQ:APVO) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($1.67) EPS for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.26. Sell-side analysts anticipate that Aptevo Therapeutics will post -8.86 earnings per share for the current year.

Institutional Trading of Aptevo Therapeutics

A hedge fund recently bought a new stake in Aptevo Therapeutics stock. Armistice Capital LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 749,234 shares of the biotechnology company’s stock, valued at approximately $229,000. Armistice Capital LLC owned 18.36% of Aptevo Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.